Sugi Predict

Sugi Predict / Compounds / SCHEMBL20129043

SCHEMBL20129043

SCHEMBL20129043

Cn1c2ccncc2c2ccc(-c3ccc(OC4CN(C(=O)OC(C)(C)C)C4)nc3)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 6/20 0.41
▸ FAAH O00519 5/20 0.41
▸ GPR119 Q8TDV5 3/20 0.40
▸ PIK3CA P42336 3/20 0.39
▸ CACNB4 O00305 1/20 0.39
▸ CACNA1A O00555 1/20 0.39
▸ CACNA1G O43497 1/20 0.39
▸ CACNG3 O60359 1/20 0.39
▸ CACNA1F O60840 1/20 0.39
▸ CACNA1H O95180 1/20 0.39
▸ CACNB3 P54284 1/20 0.39
▸ CACNA2D1 P54289 1/20 0.39
▸ CACNG7 P62955 1/20 0.39
▸ CACNA1B Q00975 1/20 0.39
▸ CACNA1D Q01668 1/20 0.39
▸ CACNB1 Q02641 1/20 0.39
▸ CACNG1 Q06432 1/20 0.39
▸ CACNB2 Q08289 1/20 0.39
▸ CACNA1S Q13698 1/20 0.39
▸ CACNA1C Q13936 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20133113 0.91 GPR119 (0.50) PIK3CDGPR119CACNB4CACNA1ACACNA1G
SCHEMBL27098515 0.90 GPR119 (0.42) PIK3CDGPR119PIK3CABTKPIK3CB
SCHEMBL27098541 0.90 GPR119 (0.42) PIK3CDGPR119PIK3CABTK
SCHEMBL27098458 0.90 PIK3CD (0.38) PIK3CDFAAHGPR119PIK3CABTK
SCHEMBL20129160 0.89 FAAH (0.37) PIK3CDFAAHGPR119PIK3CABTK
SCHEMBL20129046 0.89 PIK3CD (0.39) PIK3CDGPR119PIK3CABTKTBK1
SCHEMBL20129147 0.89 FAAH (0.41) PIK3CDFAAHGPR119PIK3CACACNB4
SCHEMBL29547814 0.89 SGMS2 (0.37) PIK3CDFAAHGPR119PIK3CABTK
SCHEMBL27152337 0.89 SGMS2 (0.37) PIK3CDFAAHGPR119PIK3CABTK
SCHEMBL27097899 0.89 SGMS2 (0.37) PIK3CDFAAHGPR119PIK3CABTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 — — WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 — — US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN PIK3CD 2235/4885FAAH 4345/4885GPR119 3791/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 PIK3CD 2652/4885FAAH 4290/4885GPR119 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.